BioCentury
ARTICLE | Strategy

Beleaguered CellPro pushes back

March 30, 1998 8:00 AM UTC

WASHINGTON - Armed with new FDA panel support for broadening the label of its Ceprate SC System, CellPro Inc. now hopes to throw two monkey wrenches into the competition's plans to take over the stem cell separation market.

The company has continued to sell Ceprate under restrictive court orders, including payment of the bulk of profits to the plaintiffs. But CPRO continues to set backfires to buy time while it appeals...